Trials / Completed
CompletedNCT04489121
The Efficacy of Preseasonal Omalizumab Treatment
The Efficacy of Preseasonal Omalizumab Treatment in Seasonal Allergic Rhinitis Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Beijing Tongren Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Allergic rhinitis (AR) is induced by an immunoglobulin E (IgE)-mediated reaction in the allergen-sensitized subjects, affecting 10% to 40% of the world population. AR could be divided into two kinds, perennial AR and seasonal AR (SAR). In recent years, biologics have become promising drugs for allergic diseases. The efficacy and safety of Omalizumab in treating SAR have been well proven by previous studies. However, the efficacy in preseasonal treatment for SAR has not yet been studied before.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season. |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2020-09-26
- Completion
- 2020-10-01
- First posted
- 2020-07-28
- Last updated
- 2021-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04489121. Inclusion in this directory is not an endorsement.